

**DRUG PLASMA LEVEL QUANTIFICATION BY LC-MS/MS | CATALOGUE 2024**

Service of Clinical Pharmacology - Laboratory PCL8 - CHUV- Lausanne

Prof. Laurent Decosterd, Dr Eva Choong Tel. 021 314 42 71 (Email: labo.pharmaco-clin@chuv.ch)

In case of **TDM clinical interpretation**: supplement 3.60 CHF / min (Tarmed 00.0141)

Prof. C. Marzolini Tel: 021 314 25 00 or 021 314 14 04

Drugs	Trademark (examples)	TDM (1)	Drugs	Trademark (examples)	TDM (1)
<b>ANTIBIOTICS (LA 1061, pts 166.5) - Analyses every working day (except: *Mo, Wed, Fri; ** Mo, Thur)</b>					
<b>Amoxicillin</b>	Clamoxyl	B	<b>Flucloxacillin</b>	Floxapen	B
<b>Cefazolin*</b>	Kefzol	B	Hydroxychloroquine*	Plaquenil	D
<b>Cefepime</b>	Maxipime	A	Imipenem	Tienam	B
<b>Ceftazidime</b>	Fortam	B	<b>Levofloxacin*</b>	Tavanic	D
Ceftolozane*	Zerbaxa	D	<b>Linezolid*</b>	Zyvoxid	B
<b>Ceftriaxone</b>	Rocephine	B	Meropenem	Meronem	B
<b>Ciprofloxacin*</b>	Ciproxine	C	Oritavancin**	Tenkasi	C
<b>Clindamycin*</b>	Dalacin	C	Penicillin G (= benzylpenicillin)*	«Grünenthal»	C
Colistin (+ Colistin methanesulfonate)	Colimycine	B	<b>Piperacillin</b>	Tazobac	B
<b>Daptomycin</b>	Cubicin	B	<b>Rifampicin</b>	Rimactan	C
Doxycycline*	Vibramycin	D	Tigecyclin*	Tygacil	C
<b>Ertapenem</b>	Invanz	B			

<b>ANTIFUNGAL DRUGS (LA 1077, pts 144) - Analyses twice a week (Monday and Thursday)</b>					
Anidulafungin	Eraxis	B	<b>Itraconazole /Hydroxy-Itraconazole</b>	Sporanox	B
Caspofungin	Cancidas	B	<b>Posaconazole</b>	Noxafil	B
<b>Fluconazole</b>	Diflucan	B	<b>Voriconazole</b>	Vfend	A
<b>Isavuconazole</b>	Cresemba	C			

<b>ANTIVIRALS (LA 1084, pts 144) - Analyses twice a week (Tuesday, Friday)</b>					
Aciclovir	Zovirax	B	Valaciclovir	Valtrex	B
Ganciclovir	Cymevene	B	Valganciclovir	Valcyte	B
Letermovir	Prevymis	C			

<b>ANTIRETROVIRALS (LA 1084, pts 144) - Analyses once a week (Wednesday to Friday)</b>					
Abacavir	Ziagen, in Triumeq	C	Emtricitabine	Emtriva, in Descovy	C
<b>Atazanavir</b>	Reyataz	B	<b>Etravirine</b>	Intelence	B
<b>Bictegravir</b>	Biktarvy	B	<i>Fostemsavir/Temsavir</i>	<i>Rukobia</i>	C
<b>Cabotegravir</b>	Vocabria	B	Lamivudine	Trizivir, in Triumeq	C
<b>Darunavir</b>	Prezista	B	<b>Maraviroc</b>	Celsenti	B
<b>Dolutegravir</b>	Tivicay, in Triumeq	B	<b>Nevirapine</b>	Viramune	B
<b>Doravirine</b>	Pifeltro, in Delstrigo	B	<b>Raltegravir</b>	Isentress	B
<b>Efavirenz</b>	Stocrin	A	<b>Rilpivirine</b>	Edurant, Rekambys	B
<b>Elvitegravir</b>	Stribild	B	Tenofovir	Viread, in Descovy	B

<b>ANTITUBERCULOSIS DRUGS (LA 1061, pts 166.5) - Analyses once a week (Thursday)</b>					
Bedaquiline	Sirturo (EMA)	C	Pretomanid	Dovprela (EMA)	C
Cycloserine	Seromycin (FDA)	C	Pyrazinamide	in Rimstar	B
Clofazimine	Lamprene	C	Rifabutin	Mycobutin	C
Delamanid (+metabolite DM6705)	Delyba (EMA)	C	Rifampicin	Rimactan, in Rimstar	B
Ethambutol	Myambutol, in Rimstar	B	Rifapentine	Priftin (FDA)	C
Isoniazid (+acetyl-isoniazid)	Rimactazid, in Rimstar	B	Sutezolid		C
Moxifloxacin	Avalox	C			

<b>ANTIPILEPTICS (LA 1069, pts 126) - Analyses every working day</b>					
Brivaracetam	Briviact	B	Oxcarbazepine (OH-Oxcarbazepine)	Trileptal	B
Carbamazepine (+ CBZ-epoxide)	Tegretol	B	Perampanel	Fycompa	B
Eslicarbazepine	Zebinix	B	Pregabalin	Lyrica	C
Gabapentin	Neurotin	B	Rufinamide	Inovelon	B
Lacosamide	Vimpat	B	Topiramate	Topamax	B
Lamotrigine	Lamictal	B	Sulthiame	Ospolot	C
Levetiracetam	Keppra	B	Zonisamide	Zonegran	B



## DRUG PLASMA LEVEL QUANTIFICATION BY LC-MS/MS | CATALOGUE 2024

Service of Clinical Pharmacology - Laboratory PCL8 - CHUV- Lausanne

Prof. Laurent Decosterd, Dr Eva Choong Tel. 021 314 42 71 (Email: labo.pharmaco-clin@chuv.ch)

Drugs	Trademark (examples)	TDM (1)	Drugs	Trademark (examples)	TDM (1)
<b>TARGETED ANTICANCER DRUGS (LA 1772, pts 126) - Analyses once a week (Monday, Tuesday)</b>					
Abemaciclib	Verzenio	C	Osimertinib	Tagrisso	C
Axitinib	Inlyta	C	Palbociclib	Ibrance	D
Bosutinib	Bosulif	C	Pazopanib	Votrient	C
Cobimetinib	Cotellic	D	Ponatinib	Iclusig	D
Dabrafenib	Tafinlar	D	Regorafenib (+ M2,M5)	Stivarga	D
<b>Dasatinib</b>	Sprycel	C	Ruxolitinib	Jakavi	D
Erlotinib	Tarceva	D	<b>Sorafenib</b>	Nexavar	C
Gefitinib	Iressa	D	<b>Sunitinib</b>	Sutent	C
Ibrutinib	Imbruvica	D	<b>Tamoxifen / Endoxifen</b>	Tamoxifen	B
<b>Imatinib</b>	Glivec	A	Trametinib	Mekinist	C
<b>Nilotinib</b>	Tasigna	C	Vemurafenib	Zelboraf	C
Olaparib	Lynparza	C			

<b>IMMUNOSUPPRESSIVE AGENTS (LA 1469 pts 135) AND CYTOSTATICS (LA 1772, pts 126) - Analyses once a week (Wednesday thiopurines, Thursday mycophenolate)</b>					
<b>6-Mercaptopurine (6-TGN, 6-MMP)</b>	Puri-Nethol, Xaluprine	B	Mycophenolic acid (+ MPAG)	CellCept, Myfortic	C
<b>6-Thioguanine (6-TGN)</b>	Lanvis	B	<i>Asparaginase activity</i>		B
<b>Azathioprine (6-TGN, 6-MMP)</b>	Imurek	B	<i>Thiopurine S-methyltransferase (TPMT) activity</i>		C

<b>OTHERS <sup>(2)</sup> - Analyses on demand</b>					
Levosimendan	Simdax	D	Lumacaftor	in Orkambi	D
Elexacaftor (+M23)	in Trikafta		Tezacaftor (+M1)	in Trikafta	D
Ivacaftor (+M1)	in Orkambi, Trikafta	D			

### MATERIAL FOR ALL ANALYSES : 4.9ml K-EDTA tube

All pre-analytical information on: [www.chuv.ch/analyses](http://www.chuv.ch/analyses)

*In gray italic: in development, please contact the laboratory for further details.*

**In bold: In the process of ISO 15189:2022 environnement**

(1) Availability of clinical interpretation (by decreasing relevance):

**A.** TDM is well established and reference intervals are defined. **B.** TDM can be performed and reference intervals are available. **C.** There is no clear target interval and TDM interpretation is limited to pharmacokinetic plausibility. **D.** Benefit of TDM needs to be established. Limited pharmacokinetic data. Result provided without clinical interpretation.

(2) The patient should be informed that the analyse is not within LA list and generally not covered by health insurance, see link below

[OFSP Analyselist](#)

Please contact the laboratory for research into *i)* the development of LC-MS/MS methods for the quantification of drugs (R&D), as well as *ii)* methods already validated for the quantification of antimalarial drugs; certain antibiotics including anti-tuberculosis drugs (macrolides, Bactrim, cefiderocol, ceftaroline, ceftobiprole, cefuroxime, PAS, prothionamide, streptomycin); JAK inhibitors; CFTR modulators; or levosimendan.

v.2024.d